Specifically, downregulation of miR-26 correlated with enhanced angiogenic potential of HCC and gain-of-function studies showed that miR-26 was able to inhibit expression of vascular endothelial growth factor A (VEGFA) which subsequently suppressed tumor promoting properties of HCC cells such as proliferation, migration and in vivo tumor angiogenesis. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.